Activin and Inhibin

GSK2647544 is an orally available, selective inhibitor of Lp-PLA2. Lipoprotein-associated phospholipase (Lp-PLA2) is a calcium-independent phospholipase A2 with proinflammatory activities that is primarily secreted by monocyte-derived

GSK2647544 is an orally available, selective inhibitor of Lp-PLA2. Lipoprotein-associated phospholipase (Lp-PLA2) is a calcium-independent phospholipase A2 with proinflammatory activities that is primarily secreted by monocyte-derived

GSK2807 Trifluoroacetate is a potent, selective and SAM-competitive inhibitor of SMYD3 , with a K i of 14 nM and an IC 50 of 130 nMIn VitroA high-resolution crystal structure reveals that GSK2807 bridges the gap between the SAM-binding pocket and

GSK2807 Trifluoroacetate is a potent, selective and SAM-competitive inhibitor of SMYD3 , with a K i of 14 nM and an IC 50 of 130 nMIn VitroA high-resolution crystal structure reveals that GSK2807 bridges the gap between the SAM-binding pocket and

GSK2807 Trifluoroacetate is a potent, selective and SAM-competitive inhibitor of SMYD3 , with a K i of 14 nM and an IC 50 of 130 nMIn VitroA high-resolution crystal structure reveals that GSK2807 bridges the gap between the SAM-binding pocket and

GSK2807 Trifluoroacetate is a potent, selective and SAM-competitive inhibitor of SMYD3 , with a K i of 14 nM and an IC 50 of 130 nMIn VitroA high-resolution crystal structure reveals that GSK2807 bridges the gap between the SAM-binding pocket and

GSK2807 Trifluoroacetate is a potent, selective and SAM-competitive inhibitor of SMYD3 , with a K i of 14 nM and an IC 50 of 130 nMIn VitroA high-resolution crystal structure reveals that GSK2807 bridges the gap between the SAM-binding pocket and

GSK2807 Trifluoroacetate is a potent, selective and SAM-competitive inhibitor of SMYD3 , with a K i of 14 nM and an IC 50 of 130 nMIn VitroA high-resolution crystal structure reveals that GSK2807 bridges the gap between the SAM-binding pocket and

GSK2850163 is a novel inhibitor of inositol-requiring enzyme-1 alpha ( IRE1α ) which can inhibit IRE1α kinase activity and RNase activity with IC 50 s of 20 and 200 nM, respectively.In VitroGSK2850163 is a novel inhibitor of inositol-requiring

GSK2850163 is a novel inhibitor of inositol-requiring enzyme-1 alpha ( IRE1α ) which can inhibit IRE1α kinase activity and RNase activity with IC 50 s of 20 and 200 nM, respectively.In VitroGSK2850163 is a novel inhibitor of inositol-requiring

GSK2850163 is a novel inhibitor of inositol-requiring enzyme-1 alpha ( IRE1α ) which can inhibit IRE1α kinase activity and RNase activity with IC 50 s of 20 and 200 nM, respectively.In VitroGSK2850163 is a novel inhibitor of inositol-requiring

GSK2850163 is a novel inhibitor of inositol-requiring enzyme-1 alpha ( IRE1α ) which can inhibit IRE1α kinase activity and RNase activity with IC 50 s of 20 and 200 nM, respectively.In VitroGSK2850163 is a novel inhibitor of inositol-requiring